Open Access
Subscription Access
Classification of Ophthalmic Drugs: Understanding the Vision of Medication
Abstract
Ophthalmic drugs play an important role regarding the treatment of different eye condit conditions, varying from infections to glaucoma. Antibiotics, which are typically used to treat corneal ulcers and conjunctivitis, combat bacterial infections. Antiviral medications target viruses that cause conditions like herpes simplex keratitis.Anti fungal drugs fight against fungal infections specifically in the cornea. Corticosteroids manage inflammation regarding conditions namely uveitis or allergic contact conjunctivitis. Non steroidal anti_ inflammatory drugs ( NSAIDs ) give relief particularly from inflammation and pain, often used post_ surgery. Antiglaucoma drugs namely beta_ blockers decrease intraoclar pressure (IOP) by reducing aqueous humor production. Alpha agonists decrease IOP bt increasing fluid drainage. Prostaglandin analogs enhance the outflow of aqueous humor to reducing IOP. Carbonic anhydrase inhibitors decrease IOP by stopping the action of carbonic anhydrase enzyme. Mydriatics dilate the pupil particularly for proper examination of the retina and to manage certain conditions. Cyclopegics paralyze particularly ciliary muscle. Assisting I. Conditions namely uveitis. Artificial tears provide moisture and relieve dry eyes. Ocular lubricants assist in conditions where natural tear production is not sufficient. Vasoconstrictors, for example, are decongestants that reduce redness by narrowing blood vessels, especially in the conjunctiva. Anti_ allergic agents like Anti histamines manage allergic conjunctivitis by inhibiting histamin receptors. Diagnostic agent such as fluorescein is used for corneal and Conjuctival Staining to detect abnormalities. Carbonic anhydrase inhibitors are helpful not only for glaucoma but also for certain corneal conditions. Rho kinase inhibitors are used fir especially for glaucoma treatment. Finally it is concluded that it is imperative for healthcare practitioners for healthcare practitioners to consider the patients overall health, existing medications and the specific eye condition when choosing the appropriate ophthalmic drug.
References
Delli, K., Spijkervet, F. K., Kroese, F. G., Bootsma, H., & Vissink, A. (2014). Xerostomia. Saliva: Secretion and Functions, 24, 109-125.
Davies, A. N., & Thompson, J. (2015). Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy. Cochrane Database of Systematic Reviews, (10).
Carlson, A. B., & Kraus, G. P. (2018). Physiology, cholinergic receptors.
Pronin, A. N., Wang, Q., & Slepak, V. Z. (2017). Teaching an old drug new tricks: Agonism, antagonism, and biased signaling of pilocarpine through M3 muscarinic acetylcholine receptor. Molecular pharmacology, 92(5), 601-612.
Tanasiewicz, M., Hildebrandt, T., & Obersztyn, I. (2016). Xerostomia of various etiologies: A review of the literature. Advances in clinical and experimental medicine: official organ Wroclaw Medical University, 25(1), 199-206.
Pakala, R. S., Brown, K. N., & Preuss, C. V. (2019). Cholinergic medications.
Infeld, D. A., & O'Shea, J. G. (1998). Glaucoma: diagnosis and management. Postgraduate medical journal, 74(878), 709-715.
Prum, B. E., Lim, M. C., Mansberger, S. L., Stein, J. D., Moroi, S. E., Gedde, S. J., ... & Williams, R. D. (2016). Primary open-angle glaucoma suspect preferred practice pattern® guidelines. Ophthalmology, 123(1), P112-P151.
Mahabadi, N., Foris, L. A., & Tripathy, K. (2017). Open angle glaucoma.
Weinreb, R. N., & Khaw, P. T. (2004). Primary open-angle glaucoma. The lancet, 363(9422), 1711-1720.
Smith, S. A., & Smith, S. E. (1983). Evidence for a neuropathic aetiology in the small pupil of diabetes mellitus. British Journal of Ophthalmology, 67(2), 89-93.
Pukrushpan, P., Tulvatana, W., & Kulvichit, K. (2006). Intraocular pressure change following application of 1% tropicamide for diagnostic mydriasis. Acta Ophthalmologica Scandinavica, 84(2), 268-270.
Hofmeister, E. M., Kaupp, S. E., & Schallhorn, S. C. (2005). Comparison of tropicamide and cyclopentolate for cycloplegic refractions in myopic adult refractive surgery patients. Journal of Cataract & Refractive Surgery, 31(4), 694-700.
Nakamura, T., Matsui, M., Uchida, K., Futatsugi, A., Kusakawa, S., Matsumoto, N., ... & Mikoshiba, K. (2004). M3 muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. The Journal of physiology, 558(2), 561-575.
Betz, A. J., McLaughlin, P. J., Burgos, M., Weber, S. M., & Salamone, J. D. (2007). The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology, 194, 347-359.
Portes, A. J. F., Barbosa, A. C., de Mello, G. L., Lopes, M. A., & Cavalcanti, R. S. (2012). Tropicamide 1% mydriatic effect: comparison between spray in closed eyes and eye drops in open eyes. Journal of ocular pharmacology and therapeutics, 28(6), 632-635.
Akman A, Aydin P. (1999). Comparison of mydriatic efficacy of spray application and drop instillation of tropicamide 1%. Eye (Lond). 13(5), 653-5.
Wong, C. Y., Fan, D. S., Yu, C. B., & Lam, D. S. (2003). Topical mydriatic and cycloplegic spray for Chinese children. Journal of Pediatric Ophthalmology & Strabismus, 40(6), 349-352.
Bremond-Gignac, D., Jacqz-Aigrain, E., Abdoul, H., Daruich, A., Beresniak, A., Baud, O., ... & CLAIR FO Study Group. (2019). Ophthalmic insert versus eye drops for mydriasis in neonates: a randomized clinical trial. Neonatology, 115(2), 142-148.
Vuori, M. L., Kaila, T., Iisalo, E., & Saari, K. M. (1994). Systemic absorption and anticholinergic activity of topically applied tropicamide. Journal of Ocular Pharmacology and Therapeutics, 10(2), 431-437.
van Minderhout, H. M., Joosse, M. V., Grootendorst, D. C., & Schalij-Delfos, N. E. (2015). Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study. BMJ open, 5(12), e008798.
Lee, J. M., Kodsi, S. R., Gaffar, M. A., & Rubin, S. E. (2014). Cardiopulmonary arrest following administration of Cyclomydril eyedrops for outpatient retinopathy of prematurity screening. Journal of American Association for Pediatric Ophthalmology and Strabismus, 18(2), 183-184.
Shiuey, Y., & Eisenberg, M. J. (1996). Cardiovascular effects of commonly used ophthalmic medications. Clinical cardiology, 19(1), 5-8.
Shiuey, Y., & Eisenberg, M. J. (1996). Cardiovascular effects of commonly used ophthalmic medications. Clinical cardiology, 19(1), 5-8.
Lavanya, R., Baskaran, M., Kumar, R. S., Wong, H. T., Chew, P. T., Foster, P. J., ... & Aung, T. (2012). Risk of acute angle closure and changes in intraocular pressure after pupillary dilation in Asian subjects with narrow angles. Ophthalmology, 119(3), 474-480.
Pandit, R. J., & Taylor, R. (2000). Mydriasis and glaucoma: exploding the myth. A systematic review. Diabetic medicine, 17(10), 693-699.
Raison‐Peyron, N., Du Thanh, A., Demoly, P., & Guillot, B. (2009). Long‐lasting allergic contact blepharoconjunctivitis to phenylephrine eyedrops. Allergy, 64(4), 657-658.
Vu, B., Wong, A., & Marcus-Freeman, S. (2017). Allergic reaction to phenylephrine. Federal Practitioner, 34(2), 41.
Villarreal, O. (1998). Reliability of diagnostic tests for contact allergy to mydriatic eyedrops. Contact dermatitis, 38(3), 150-154.
Geyer, O., Yust, I., & Lazar, M. (1988). Allergic blepharoconjunctivitis due to phenylephrine. Journal of Ocular Pharmacology and Therapeutics, 4(2), 123-126.
Drugs and Lactation Database (LactMed®). (2021). National Institute of Child Health and Human Development; Bethesda (MD). Tropicamide.
Anastasi, L. M., Ogle, K. N., & Kearns, T. P. (1968). Effect of pilocarpine in counteracting mydriasis. Archives of Ophthalmology, 79(6), 710-715.
Nelson, M. E., & Orton, H. P. (1987). Counteracting the effects of mydriatics: does it benefit the patient?. Archives of Ophthalmology, 105(4), 486-489.
Mapstone, R. (1977). Dilating dangerous pupils. British Journal of Ophthalmology, 61(8), 517-524.
Doughty, M. J., & Lyle, W. M. (1992). A review of the clinical pharmacokinetics of pilocarpine, moxisylyte (thymoxamine), and dapiprazole in the reversal of diagnostic pupillary dilation. Optometry and vision science, 69(5), 358-368.
Refbacks
- There are currently no refbacks.